ArticleProceedings (Baylor University. Medical Center)2025
Primary cutaneous leiomyosarcoma: demographics and survival benefit of surgical management in a US population.
Article in Proceedings (Baylor University. Medical Center), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cutaneous Leiomyosarcoma of the Skin: An Updated Review of Epidemiology, Pathogenesis, and Management.International journal of dermatology · 2026Review
- Gaining a clearer picture of primary cutaneous leiomyosarcoma.Proceedings (Baylor University. Medical Center) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Leiomyosarcoma of the skin is a rare malignant mesenchymal neoplasm categorized as cutaneous or subcutaneous. This study identified demographic and pathological factors affecting the prognosis and treatment of leiomyosarcoma of the skin. Methods: Data of patients with skin leiomyosarcoma was extracted from 2000 to 2020 using the Surveillance, Epidemiology, and End Results database. Propensity score matching and prognostic nomograms were used to analyze survival rate predictions. Results: Most patients were >65 years of age (50.5%), male (78.8%), and White (88.5%). The overall 5-year survival was 79.9% (95% confidence interval [CI] = 77.4-82.6), and the 5-year cause-specific survival rate was 95.7% (95% CI = 94.2-97.2). Based on treatment, the 5-year cause-specific survival rate was 82.9% (95% CI = 80.3-85.6) for surgery only, 60.2% (95% CI = 47.7-76.0) for both radiation and surgery, and 68.2% (95% CI = 58.9-78.9) for no treatment. Multivariable analysis showed that head and neck tumors were associated with worse mortality. Conclusion: The results provide valuable insights that could shape development of future clinical protocols for skin leiomyosarcoma and impact patient care and treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.